-
Better Sleep, Better Function: New Study Links Sleep Quality to Clinical Outcomes in Huntington’s Disease
Latest News
-
Keeping up with HD research just got easier: Introducing the HDBuzz Trial Tracker
⏱️6 min read | Ever wonder when to expect the next update from a clinical trial for Huntington’s disease? The HDBuzz Trial Tracker puts future updates for HD trials on a clear timeline, with deeper explanations in our articles when you want them.
-
Vaccines and Neurodegeneration: Lessons for Huntington’s Disease?
⏱️5 min read | Research suggests vaccines may reduce dementia risk by 20%. Infections cause inflammation and toxic byproducts that mitochondria normally clear. In HD, where mitochondria are impaired, vaccination is especially crucial.
-
UniQure Secures Type A Meeting with FDA: What This Means for AMT-130
⏱️6 min read | UniQure secured a Type A FDA meeting, a high-priority discussion for urgent issues. Within 30 days, both sides will discuss what kind of data package might support the advancement of AMT-130 in the US.
-
Putting Huntington’s disease medications to the test: results from the Neuro-HD trial
⏱️6 min read | A clinical trial, Neuro-HD, compared 3 common drugs for HD symptoms. The 1 year study found no “best” medication, but clear differences between treatments. The results support a personalised, symptom-by-symptom approach to HD treatment.
-
HDBuzz Is Officially Independent: What This Means, and Why It Matters
We’re entering a new chapter. HDBuzz is now an independent organisation, strengthening our ability to report clearly, critically, and responsibly on HD research.
-
2025: Year in Review
⏱️34 min read | As we usher in 2026, we look back on the landmark clinical trial findings, advancements in research, regulatory disappointments, and thunderous community unity that will define 2025 for the Huntington’s disease community.
-
Break Up With Your CAGs: How Three Letters Could Change Huntington’s Disease
Scientists engineered stem cells with “interrupted” CAG repeats to break up the toxic stretch. This may stop expansion, and could improve problems in cells that model Huntington’s disease. This study suggests that DNA spelling can drive the disease.
-
First participants dosed in new POINT-HD huntingtin-lowering trial
POINT-HD has begun dosing its first participants with the drug RG6496, marking an early but important step for a new selective huntingtin-lowering approach.
-
A road less traveled: how making less huntingtin can alter somatic instability and may delay symptoms
CAG repeats can get longer over time as the HD gene is used, like the growing potholes and cracks in an old road. New research finds that blocking cells from using their HTT gene slows this wear and tear, which might slow the onset of symptoms in HD.
-
A tug-of-war at the DNA: how Huntington’s repeats grow and shrink
A new study from Switzerland sheds light on how the CAG repeat number in the Huntington’s disease gene can grow or shrink inside our cells.
-
UniQure Receives FDA Meeting Minutes on AMT-130 While Community Support Remains Strong
UniQure received FDA’s meeting minutes on AMT-130. While there were no new updates, the community’s response has been powerful, with 41K+ petition signatures & unified advocacy from major HD orgs.
HDBuzz Trial Tracker
Progress update for NCT06585449 – A Study to Evaluate ALN-HTT02
Additional insights from Phase 2 study results and update on plans for Phase 3 trial for votoplam
